RxDoctor Payments Data

Jessica Slattery

Nurse Practitioner · Auburn, INNPI 1245518927

Payments from drug & device makers

$2,458in general payments, 2019–2025

Across 135 payments — averaging $18.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$463
  • AbbVie$331
  • Novo Nordisk$316
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$231
  • Amgen$156
  • Exact Sciences$132
  • plus $830 from 16 others

What the payments were for

  • Food & beverage$2,458100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,458 in reported general payments places this provider in the 85th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$18,277
Medicare patients
127
Services billed
946

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin12$14,917
EliquisApixaban15$13,408
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,598
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$3,112
Albuterol Sulfate HfaAlbuterol Sulfate54$1,196
Levothyroxine Sodium122$862
Atorvastatin Calcium115$726
Fluticasone Propionate53$532
Pantoprazole Sodium39$465
Bupropion XlBupropion Hcl17$465
Omeprazole69$440
Metoprolol Succinate42$422
SynthroidLevothyroxine Sodium16$373
Gabapentin47$362
Glimepiride48$345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$90$14,91712 claims
PfizerEliquis$38$13,40815 claims
GSKAnoro Ellipta$44$5,59812 claims
AbbVieSynthroid$331$37316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Auburn

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →